UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Blood, 2022-11, Vol.140 (Supplement 1), p.13285-13286

2022

Link zum Volltext

Verfügbarkeit prüfen

Representation of the population in need for pivotal clinical trials in lymphomas

Blood, 2023-08, Vol.142 (9), p.846

2023

Link zum Volltext

Verfügbarkeit prüfen

Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.5274-5275

2022

Link zum Volltext

Verfügbarkeit prüfen

Are Pivotal Trials for Drug Approval for Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms Representative of the Population Affected By These Diseases?

Blood, 2022-11, Vol.140 (Supplement 1), p.13200-13201

2022

Link zum Volltext

Verfügbarkeit prüfen

Are pivotal clinical trials for lymphomas that led to drug approval representative of the population affected by these diseases?

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.6531-6531

2022

Link zum Volltext

Verfügbarkeit prüfen

Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected By These Diseases?

Blood, 2021-11, Vol.138 (Supplement 1), p.846-846

2021

Link zum Volltext

Verfügbarkeit prüfen

Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy

Blood, 2022-11, Vol.140 (Supplement 1), p.8929-8929

2022

Link zum Volltext

Verfügbarkeit prüfen

Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3022-3022

2021

Link zum Volltext

Verfügbarkeit prüfen

Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?

Journal of clinical oncology, 2022-11, Vol.40 (32), p.3719-3729

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

Blood, 2020-11, Vol.136 (Supplement 1), p.22-22

2020

Link zum Volltext

Verfügbarkeit prüfen

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Haematologica (Roma), 2021-11, Vol.106 (11), p.2853-2858

2021

Link zum Volltext

Verfügbarkeit prüfen

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Blood, 2020-11, Vol.136 (Supplement 1), p.40-41

2020

Link zum Volltext

Verfügbarkeit prüfen

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.7522-7522

2020

Link zum Volltext

Verfügbarkeit prüfen

Incidence and outcomes of immune checkpoint inhibitor-related myositis

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15128-e15128

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitor (ICI)-related pneumonitis among patients with lung cancer admitted to an Oncology Hospitalist Service: Treatment patterns and hospitalization outcomes

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21054-e21054

2021

Link zum Volltext

Verfügbarkeit prüfen

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e18539-e18539

2019

Link zum Volltext

Verfügbarkeit prüfen

Activity of venetoclax-based therapy in TP53 -mutated acute myeloid leukemia

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7034-7034

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML)

Blood, 2011-11, Vol.118 (21), p.4443-4443

2011

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)

Blood, 2011-11, Vol.118 (21), p.2764-2764

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

KollektionPublisher or Other Site

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(4)
Science & Technology
(4)
Humans
(3)
Oncology
(3)
Acute Myeloid Leukemia
(2)
Chemotherapy
(2)
Female
(2)
Leukemia
(2)
Male
(2)
Mutation
(2)
Myeloid Leukemia
(2)
Remission
(2)
United States - Epidemiology
(2)
Aged
(1)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(1)
Black Or African American
(1)
Bridged Bicyclo Compounds, Heterocyclic - Therapeutic Use
(1)
Clinical Trials As Topic
(1)
Cytotoxicity
(1)
Dehydrogenase
(1)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations

The Financial Toxicity of FDA-Drugs Approved for Malignant Hematology

Representation of the population in need for pivotal clinical trials in lymphomas

Global Representation in Phase 2 and Phase 3 Clinical Trials for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

Are Pivotal Trials for Drug Approval for Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms Representative of the Population Affected By These Diseases?

Are pivotal clinical trials for lymphomas that led to drug approval representative of the population affected by these diseases?

Are Pivotal Trials for Drugs Approved for Leukemia, Myelodysplastic Syndromes, and Multiple Myeloma Representative of the Population Demographics Affected By These Diseases?

Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy

Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319)

Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?

Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Racial Variations in Mutational Profile in Newly Diagnosed Acute Myeloid Leukemia Patients

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia

Incidence and outcomes of immune checkpoint inhibitor-related myositis

Immune checkpoint inhibitor (ICI)-related pneumonitis among patients with lung cancer admitted to an Oncology Hospitalist Service: Treatment patterns and hospitalization outcomes

The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Activity of venetoclax-based therapy in TP53 -mutated acute myeloid leukemia

Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML)

Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts)

Aktive Filter

Suchergebnisse filtern